Windtree Therapeutics, Inc. (WINTW)
USD 0.0
(-71.76%)
USD 0.0
(-71.76%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.83 Million USD | -19.74% |
| 2022 | 2.28 Million USD | -21.19% |
| 2021 | 2.89 Million USD | -23.49% |
| 2020 | 3.78 Million USD | -40.11% |
| 2019 | 6.31 Million USD | -20.83% |
| 2018 | 7.97 Million USD | -46.84% |
| 2017 | 15 Million USD | -40.0% |
| 2016 | 25 Million USD | 0.0% |
| 2015 | 25 Million USD | 22.77% |
| 2014 | 20.36 Million USD | 10.1% |
| 2013 | 18.49 Million USD | 2702.42% |
| 2012 | 660 Thousand USD | -32.72% |
| 2011 | 981 Thousand USD | -8.4% |
| 2010 | 1.07 Million USD | -90.68% |
| 2009 | 11.48 Million USD | 13.41% |
| 2008 | 10.12 Million USD | -33.58% |
| 2007 | 15.24 Million USD | 12.05% |
| 2006 | 13.6 Million USD | 178.25% |
| 2005 | 4.89 Million USD | -35.5% |
| 2004 | 7.58 Million USD | 593.14% |
| 2003 | 1.09 Million USD | 145.84% |
| 2002 | 445 Thousand USD | 477.92% |
| 2001 | 77 Thousand USD | 60.42% |
| 2000 | 48 Thousand USD | 0.0% |
| 1999 | 48 Thousand USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | -100.0% |
| 1996 | 100 Thousand USD | 0.0% |
| 1995 | 100 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.48 Million USD | -18.91% |
| 2024 Q2 | 3.86 Million USD | 127.56% |
| 2023 FY | 1.83 Million USD | -19.74% |
| 2023 Q1 | 1.9 Million USD | -16.62% |
| 2023 Q4 | 1.83 Million USD | -15.16% |
| 2023 Q3 | 2.15 Million USD | -13.58% |
| 2023 Q2 | 2.49 Million USD | 31.3% |
| 2022 Q1 | 2.41 Million USD | -16.49% |
| 2022 Q3 | 2.77 Million USD | -15.28% |
| 2022 Q4 | 2.28 Million USD | -17.9% |
| 2022 FY | 2.28 Million USD | -21.19% |
| 2022 Q2 | 3.27 Million USD | 35.68% |
| 2021 Q2 | 3.82 Million USD | -26.91% |
| 2021 FY | 2.89 Million USD | -23.49% |
| 2021 Q4 | 2.89 Million USD | -9.82% |
| 2021 Q3 | 3.2 Million USD | -16.22% |
| 2021 Q1 | 5.23 Million USD | 38.56% |
| 2020 Q3 | 4.03 Million USD | -41.33% |
| 2020 Q4 | 3.78 Million USD | -6.2% |
| 2020 Q2 | 6.87 Million USD | 16.36% |
| 2020 FY | 3.78 Million USD | -40.11% |
| 2020 Q1 | 5.9 Million USD | -6.46% |
| 2019 FY | 6.31 Million USD | -20.83% |
| 2019 Q4 | 6.31 Million USD | -33.66% |
| 2019 Q1 | 9.45 Million USD | 18.51% |
| 2019 Q3 | 9.51 Million USD | -2.63% |
| 2019 Q2 | 9.77 Million USD | 3.42% |
| 2018 FY | 7.97 Million USD | -46.84% |
| 2018 Q3 | 5.24 Million USD | 109.96% |
| 2018 Q4 | 7.97 Million USD | 51.91% |
| 2018 Q1 | 2.5 Million USD | 0.0% |
| 2018 Q2 | 2.5 Million USD | 0.0% |
| 2017 Q2 | 25 Million USD | 0.0% |
| 2017 Q1 | 25 Million USD | 0.0% |
| 2017 FY | 15 Million USD | -40.0% |
| 2017 Q4 | - USD | -100.0% |
| 2017 Q3 | 27.6 Million USD | 10.4% |
| 2016 Q1 | 25 Million USD | 0.0% |
| 2016 FY | 25 Million USD | 0.0% |
| 2016 Q2 | 25 Million USD | 0.0% |
| 2016 Q4 | 25 Million USD | 0.0% |
| 2016 Q3 | 25 Million USD | 0.0% |
| 2015 Q1 | 20.89 Million USD | 2.63% |
| 2015 FY | 25 Million USD | 22.77% |
| 2015 Q2 | 21.47 Million USD | 2.74% |
| 2015 Q4 | 25 Million USD | 0.0% |
| 2015 Q3 | 25 Million USD | 16.43% |
| 2014 FY | 20.36 Million USD | 10.1% |
| 2014 Q3 | 19.85 Million USD | 2.5% |
| 2014 Q4 | 20.36 Million USD | 2.58% |
| 2014 Q2 | 19.36 Million USD | 2.38% |
| 2014 Q1 | 18.91 Million USD | 2.27% |
| 2013 Q1 | 6.28 Million USD | 851.82% |
| 2013 Q4 | 18.49 Million USD | 185.12% |
| 2013 Q3 | 6.48 Million USD | 1.66% |
| 2013 Q2 | 6.38 Million USD | 1.58% |
| 2013 FY | 18.49 Million USD | 2702.42% |
| 2012 Q2 | 939 Thousand USD | -3.69% |
| 2012 FY | 660 Thousand USD | -32.72% |
| 2012 Q4 | 660 Thousand USD | -27.07% |
| 2012 Q3 | 905 Thousand USD | -3.62% |
| 2012 Q1 | 975 Thousand USD | 233.9% |
| 2011 FY | 981 Thousand USD | -8.4% |
| 2011 Q4 | 292 Thousand USD | -71.0% |
| 2011 Q3 | 1 Million USD | -5.09% |
| 2011 Q2 | 1.06 Million USD | -4.67% |
| 2011 Q1 | 1.11 Million USD | 154.69% |
| 2010 Q1 | 12.09 Million USD | 5.3% |
| 2010 Q4 | 437 Thousand USD | -16.6% |
| 2010 Q2 | 5.35 Million USD | -55.74% |
| 2010 Q3 | 524 Thousand USD | -90.21% |
| 2010 FY | 1.07 Million USD | -90.68% |
| 2009 FY | 11.48 Million USD | 13.41% |
| 2009 Q1 | 12.91 Million USD | -5.45% |
| 2009 Q2 | 10.29 Million USD | -20.33% |
| 2009 Q3 | 12.3 Million USD | 19.59% |
| 2009 Q4 | 11.48 Million USD | -6.67% |
| 2008 Q1 | 14.95 Million USD | -1.9% |
| 2008 Q2 | 9.9 Million USD | -33.8% |
| 2008 FY | 10.12 Million USD | -33.58% |
| 2008 Q3 | 14.36 Million USD | 45.02% |
| 2008 Q4 | 13.66 Million USD | -4.87% |
| 2007 Q4 | 15.24 Million USD | 6.15% |
| 2007 Q1 | 13.29 Million USD | -2.31% |
| 2007 Q2 | 13.51 Million USD | 1.65% |
| 2007 FY | 15.24 Million USD | 12.05% |
| 2007 Q3 | 14.36 Million USD | 6.31% |
| 2006 Q3 | 13.28 Million USD | -2.75% |
| 2006 FY | 13.6 Million USD | 178.25% |
| 2006 Q1 | 13.2 Million USD | 170.01% |
| 2006 Q2 | 13.66 Million USD | 3.48% |
| 2006 Q4 | 13.6 Million USD | 2.41% |
| 2005 Q3 | 11.09 Million USD | 0.74% |
| 2005 Q4 | 4.89 Million USD | -55.92% |
| 2005 Q2 | 11.01 Million USD | -0.13% |
| 2005 Q1 | 11.02 Million USD | 45.43% |
| 2005 FY | 4.89 Million USD | -35.5% |
| 2004 FY | 7.58 Million USD | 593.14% |
| 2004 Q4 | 7.58 Million USD | -1.01% |
| 2004 Q3 | 7.66 Million USD | 338.72% |
| 2004 Q2 | 1.74 Million USD | 36.41% |
| 2004 Q1 | 1.28 Million USD | 17.0% |
| 2003 Q3 | 797 Thousand USD | 52.68% |
| 2003 Q2 | 522 Thousand USD | -10.92% |
| 2003 Q4 | 1.09 Million USD | 37.26% |
| 2003 FY | 1.09 Million USD | 145.84% |
| 2003 Q1 | 586 Thousand USD | 31.69% |
| 2002 Q4 | 445 Thousand USD | -69.1% |
| 2002 FY | 445 Thousand USD | 477.92% |
| 2002 Q2 | 55 Thousand USD | -16.67% |
| 2002 Q1 | 66 Thousand USD | -14.29% |
| 2002 Q3 | 1.44 Million USD | 2518.18% |
| 2001 Q2 | 39 Thousand USD | -7.14% |
| 2001 Q1 | 42 Thousand USD | -12.5% |
| 2001 Q3 | 35 Thousand USD | -10.26% |
| 2001 Q4 | 77 Thousand USD | 120.0% |
| 2001 FY | 77 Thousand USD | 60.42% |
| 2000 Q2 | 55 Thousand USD | -6.78% |
| 2000 Q1 | 59 Thousand USD | 22.92% |
| 2000 Q4 | 48 Thousand USD | -5.88% |
| 2000 Q3 | 51 Thousand USD | -7.27% |
| 2000 FY | 48 Thousand USD | 0.0% |
| 1999 FY | 48 Thousand USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | 48 Thousand USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1997 Q2 | 1.2 Million USD | 9.09% |
| 1997 FY | - USD | -100.0% |
| 1997 Q4 | - USD | -100.0% |
| 1997 Q3 | 1 Million USD | -16.67% |
| 1997 Q1 | 1.1 Million USD | 1000.0% |
| 1996 Q4 | 100 Thousand USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q3 | - USD | -100.0% |
| 1996 FY | 100 Thousand USD | 0.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1995 FY | 100 Thousand USD | 0.0% |
| 1995 Q4 | 100 Thousand USD | 0.0% |
| 1995 Q2 | 2.8 Million USD | 75.0% |
| 1995 Q1 | 1.6 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 95.559% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 55.604% |
| SQZ Biotechnologies Company | 27.47 Million USD | 93.338% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 95.781% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 93.852% |
| Mesoblast Limited | 118.7 Million USD | 98.458% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -92.983% |
| Genus plc | 233.1 Million USD | 99.215% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 37.551% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -36.203% |
| Marizyme, Inc. | 18.71 Million USD | 90.223% |
| ContraFect Corporation | 2.88 Million USD | 36.48% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -144.0% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1250.683% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -26.528% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 21.323% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 67.658% |
| MultiCell Technologies, Inc. | 202.58 USD | -903246.826% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 96.817% |
| EV Biologics, Inc. | 1.49 Million USD | -22.428% |
| Q BioMed Inc. | 4.1 Million USD | 55.474% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 94.471% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -190.441% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -48.979% |
| Biomind Labs Inc. | 735.54 Thousand USD | -148.796% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 98.933% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 85.92% |
| Skye Bioscience, Inc. | 4.61 Million USD | 60.349% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -106.066% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1193.122% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 68.83% |
| IMV Inc. | 28.88 Million USD | 93.664% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -7015.362% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 18.969% |
| GB Sciences, Inc. | 1.75 Million USD | -4.018% |
| Alpha Cognition Inc. | 1.22 Million USD | -49.954% |
| HST Global, Inc. | 98.31 Thousand USD | -1761.288% |
| CSL Limited | 12.18 Billion USD | 99.985% |
| Halberd Corporation | 150 Thousand USD | -1120.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -83.673% |
| Resverlogix Corp. | 6.49 Million USD | 71.807% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -283.246% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -615.985% |
| argenx SE | 20 Million USD | 90.85% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 95.983% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 32.44% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -17797.311% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.562% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -812.19% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 23.678% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -698.112% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 97.295% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 39.528% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -408.743% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 90.998% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1131.047% |
| BioStem Technologies, Inc. | 4.71 Million USD | 61.158% |
| ONE Bio Corp. | 19.71 Million USD | 90.718% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -631.467% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -635.767% |
| Agentix Corp. | 50 Thousand USD | -3560.0% |
| LadRx Corporation | 33.6 Thousand USD | -5345.456% |
| Cell Source, Inc. | 9.25 Million USD | 80.225% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -141.998% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -141.998% |
| NovAccess Global Inc. | 2.19 Million USD | 16.814% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 74.126% |
| Itoco Inc. | 228.37 Thousand USD | -701.307% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -767.401% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 63.275% |
| Kadimastem Ltd | 891.22 Thousand USD | -105.335% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -355.395% |
| CytoDyn Inc. | 30.07 Million USD | 93.915% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -277.877% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -420.112% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 76.598% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1393.878% |
| Rebus Holdings, Inc. | 310 Thousand USD | -490.323% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 61.354% |
| International Stem Cell Corporation | 4.17 Million USD | 56.199% |
| Bioxytran, Inc. | 1.92 Million USD | 4.935% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2832.081% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 16.09% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 77.994% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 78.684% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -17.649% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -582.836% |
| Neutra Corp. | 54.15 Thousand USD | -3279.127% |
| PureTech Health plc | 25.51 Million USD | 92.827% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -49.482% |
| IXICO plc | 472.02 Thousand USD | -287.693% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 88.194% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 97.061% |
| CSL Limited | 12.18 Billion USD | 99.985% |
| Cellectis S.A. | 92.77 Million USD | 98.028% |